Research Data Sharing IG
1.0.0 - CI Build
Research Data Sharing IG
1.0.0 - CI Build
Research Data Sharing IG, published by IEHR-Workgroup. This guide is not an authorized publication; it is the continuous build for version 1.0.0 built by the FHIR (HL7® FHIR® Standard) CI Build. This version is based on the current content of https://github.com/InteropEHRate-project/research-data-sharing/ and changes regularly. See the Directory of published versions
| LinkId | Text | Definition | Answer |
|---|---|---|---|
  3234 | Questionnaire:CRFInterval | ||
  sec1 | Patient general data | ||
  1.1 | Surname | Meier | |
| 1.2 | Name | Thomas | |
| 1.3 | Allergies | - | |
| 1.4 | Gender | AdministrativeGender male: Male | |
 1.5 | Date of birth (DD/MM/YYYY) | 1997-03-21 | |
| sec2 | Disease related data | ||
| 2.1 | Year of hypertension diagnosis | 2003 | |
| 2.2 | blood pressure measurement SYS/DIA (mmHg/mmHg) | 149/94 | |
| 2.3 | Latest creatinine (mg/dL) | 1,2 | |
| 2.4 | Current Medications | ACE inhibitors | |
| 2.5 | EKG report signal | RR interval: 0.6-1.2 seconds. P wave: 80 milliseconds. PR interval: 120-200 milliseconds | |
| 2.6 | Echocardiogram report and video | No display for Attachment | |
| 2.7 | Latest left ventricular ejection fraction (%) | 61.3 | |
| 2.8 | Latest interventricular septum thickness (mm) | 8.7 | |
| sec3 | Questionnaire on side effects | ||
| 3.1 | Name of the Drug | Fondaparinux sodium | |
| 3.2 | Type of symptom(s) | ||
| 3.3 | How long the adverse event last? | 1 day to 1 week | |
| 3.4 | Did you withdraw the drug? | false | |
| 3.5 | Did the adverse reaction require specific treatment? | false | |
| sec4 | Feasibility assessment | ||
 4.1 | Preliminary Questions | ||
| 4.1.1 | Age | 23 | |
| 4.1.2 | Sex | Male | |
| 4.1.3 | Educational Level | Graduate | |
| 4.1.4 | Urban Zone (rural/ urban) | urban | |
| 4.1.5 | Profession (if retired, previously exercised | Student | |
| 4.1.6 | Do you routinely use apps of your smartphone/table in your daily life (excluded messages and phone calls)? | true | |
| 4.1.7 | Do you have wifi/xDSL/3g/4g connection in you home | true | |
| 4.2 | What satisfaction level do you have about the clinical staff explanation or instruction manual for use and maintenance of the system? | Satisfied | |
| 4.3 | How would you rate the ease of use of the platform? | Easy | |
| 4.4 | What satisfaction level do you have about the received clinical care provided by the use of the platform? | Satisfied | |
| 4.5 | If you had any technical problem, were you satisfied with the solution of it? | Dissatisfied | |
| 4.6 | How would you rate the mobile device operation? | Very safe | |
| 4.7 | Has the INTEROPEHRATE System helped you understand better your disease? | Strongly Agree | |
| 4.8 | Has the INTEROPEHRATE System allowed you to have more autonomy to access to hospitals or care Centres? | Strongly Agree | |
| 4.9 | Do you consider that INTEROPEHRATE system has a major role i communicating with foreign healthcare provider? | Agree | |
| 4.10 | The INTEROPEHRATE System has had a positive impact in the way that you live your disease? | Agree | |
| 4.11 | Do you consider that your family/caregivers have been benefited from your use of the INTEROPEHRATE system by a lower possibility of psychological or physical burden that can cause the disease? | Strongly Agree | |
| 4.12 | Please mark from 1 to 4 your satisfaction level about the INTEROPEHRATE system (1 ist considered as Very dissatisfied and 4 as Very satisfied)? | 3.8 | |
| 4.13 | Please mark from 1 to 4, if you would recommend other people to use the INTEROPEHRATE System | 3.7 | |
| Documentation for this format | |||